( did not test for possible learning and ...)Cortex Area Thinner in Youth with Alzheimers-Related Gene,Health

did not test for possible learning and memory deficits, the researchers found no difference in IQ attributable to ApoE gene type. Nor did the E4 variant accelerate loss of cortex tissue. The differences were fixed, and didn't progress. In fact, the researchers noted evidence that ApoE4 may even promote survival in infancy and protect the brains thinking capacity against damage from infectious illness.
"In the future we hope to determine whether this thinner cortex is associated with differences in brain activity during tasks of learning and memory in children, said Shaw.

Also participating in the research were: Kristin Taylor, A. Blyth Rose, Deanna Greenstein, Liv Clasen, NIMH; Jason Lerch, Jens Pruessner, Alan Evans, Montreal Neurological Institute, McGill University.

MRI scans revealed that children and adolescents with the ApoE4 gene variant, which is associated with Alzheimers disease, had a thinner entorhinal cortex, the first brain area to be affected by the brain disorder. Youth with the much rarer ApoE2 variant, thought to protect against Alzheimers, had the thickest cortex. The vertical lines in the graph show ranges of thickness, with the red dots being the averages. Source: Philip Shaw, M.D., NIMH Child Psychiatry Branch

Entorhinal cortex (red) was thinnest in youth with Alzheimers-related ApoE4 gene variant. View of left entorhinal cortex from beneath the brain, with front of brain at top. Artists rendering. Source: Philip Shaw, M.D., NIMH Child Psychiatry Branch

The National Institute of Mental Health (NIMH) mission is to reduce the burden of mental and behavioral disorders through research on mind, brain, and behavior. More information is available at the NIMH website, http://www.nimh.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia